Eyewash components

Abstract

To provide an eyewash composition capable of providing a refreshing feeling for a longer period of time and improving eye symptoms associated with VDT work. [Solution] An eyewash composition for improving eye symptoms associated with VDT (Visual Display Terminal) work, which contains (A) at least one selected from the group consisting of hyaluronic acid and its salts, and (B) a refreshing agent.

Description

[Technical Field]

[0001] This invention relates to eyewash compositions. [Background technology]

[0002] In recent years, with the widespread use of display devices such as laptop computers and the internet, VDT (Visual Display Terminal) work has become widespread in everyday life. However, continued VDT work reduces the frequency of blinking, which leads to increased eye dirt accumulation and reduced tear production, leading to dryness, foreign body sensation, dry eyes, and eye strain. Blue light is also said to be a cause of eye strain. Conventionally, heat-gelling artificial tears containing (a) methylcellulose and (b) at least one selected from the group consisting of polyethylene glycol, citric acid, and pharmaceutically acceptable salts thereof have been known, and it has been reported that this formulation can increase tear production (Patent Document 1).

[0003] In addition, washing the eyes with eyewash is useful in terms of reducing eye dirt and moistening the eyes. Furthermore, refreshing the eyes with eyewash containing a cooling agent can temporarily relieve eye fatigue, and such a cooling sensation tends to be preferred. However, the cooling sensation often does not last long. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Laid-Open No. 2003-095924 Summary of the Invention [Problem to be solved by the invention]

[0005] Therefore, the present inventors have an object to provide an eyewash composition that can provide a refreshing feeling for a longer period of time and improve eye symptoms associated with VDT work. [Means for solving the problem]

[0006] The present inventors have conducted extensive research in light of the above-mentioned problems and have found that by using hyaluronic acid in combination with a cooling agent, it is possible to prolong the cooling sensation while improving the cooling sensation of a VDT (Visual Display). The present invention was completed as a result of further investigations based on this finding, and is as follows: Item 1. An eyewash composition for improving eye symptoms associated with working with VDTs (Visual Display Terminals), comprising (A) at least one selected from the group consisting of hyaluronic acid and salts thereof, and (B) a cooling agent. Item 2. The eyewash composition according to Item 1, further comprising (C) at least one selected from the group consisting of pyridoxine, chondroitin sulfate, and salts thereof. Item 3. The eyewash composition according to Item 1 or 2, wherein the eye symptom associated with VDT work is at least one selected from the group consisting of decreased focus, dryness, foreign body sensation, dry eye, and eye strain. Item 4. The eyewash composition according to any one of Items 1 to 3, wherein the component (B) is a monoterpene. Item 5. The eyewash composition according to any one of Items 1 to 4, which is used while wearing contact lenses. [Effects of the Invention]

[0007] By using hyaluronic acid in combination with a cooling agent, it is possible to provide an eyewash composition that can improve eye symptoms associated with VDT work while providing a cooling sensation for a longer period of time. DETAILED DESCRIPTION OF THE INVENTION

[0008] The embodiments included in the present disclosure are described in further detail below.

[0009] The present disclosure encompasses an eyewash composition for improving ocular symptoms associated with working with VDTs (Visual Display Terminals), which contains (A) at least one selected from the group consisting of hyaluronic acid and its salts, and (B) a refreshing agent.

[0010] At least one selected from the group consisting of hyaluronic acid and its salts (sometimes referred to as component (A)) is a known component, and preferred examples of the salt include alkali metal salts such as sodium salts, etc. These may be used alone or in combination of two or more.

[0011] The content of component (A) is not limited as long as the effects of the present disclosure are obtained, but examples of the content in the eyewash composition include preferably 0.002 to 0.03 w / v%, more preferably 0.005 to 0.03 w / v%, even more preferably 0.01 to 0.03 w / v%, and particularly preferably 0.015 to 0.03 w / v%.

[0012] The freshening agent (sometimes referred to as component (B)) may be any agent that can be applied to the eyes as a component of an eyewash composition, and preferably includes monoterpenes. While not limiting the present disclosure, examples of the freshening agent include acyclic monoterpenes such as geraniol, citral, citronellal, citronellol, nerol, and linalool; cyclic monoterpenes such as limonene, menthol, thymol, and carvacrol; and polycyclic monoterpenes such as pinene, camphor, borneol, isoborneol, and cineol. More preferably, menthol, borneol, and camphor are used. When the freshening agent contains d-, l-, and dl-isomers, any of these may be used. These may be used alone or in combination of two or more.

[0013] The content of component (B) in the eyewash composition is not limited as long as the effects of the present disclosure are obtained, but is preferably 0.001 to 0.02 w / v%, more preferably 0.002 to 0.01 w / v%, and even more preferably 0.004 to 0.008 w / v%. The content of component (B) in the eyewash composition is not limited as long as the effects of the present disclosure are obtained, but is preferably 0.2 to 6 parts by mass, more preferably 0.2 to 4 parts by mass, and even more preferably 0.2 to 0.5 parts by mass per part by mass of component (A).

[0014] The eyewash composition of the present disclosure may further contain at least one selected from the group consisting of pyridoxine, chondroitin sulfate, and salts thereof (sometimes referred to as component (C)). From the viewpoint of further improving eye symptoms associated with VDT work, such as ocular fatigue, dryness, foreign body sensation, and focusing ability, it is preferable to incorporate component (C). Component (C) is a known component and is not limited thereto. Examples of pyridoxine salts include hydrochloride (pyridoxine hydrochloride) and inorganic acid salts such as phosphates.

[0015] Chondroitin sulfate is a mucopolysaccharide having a structure in which sulfate is ester-bonded to a sugar chain in which two sugars, D-glucuronic acid and N-acetylgalactosamine, are repeated. Examples of salts of chondroitin sulfate include, but are not limited to, alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as magnesium salt and calcium salt. Examples of salts of chondroitin sulfate include, but are not limited to, sodium chondroitin sulfate.

[0016] Although the chondroitin sulfate and salts thereof used in the present disclosure are not limited thereto, the molecular weight thereof is preferably, for example, about 5,000 to 45,000, more preferably about 10,000 to 40,000, and even more preferably about 15,000 to 30,000. The weight-average molecular weight is measured by gel filtration chromatography. Chondroitin sulfate and salts thereof are commercially available, for example, under the trade name "Extraneous Standard Sodium Chondroitin Sulfate" (Seikagaku Corporation, weight-average molecular weight 20,000).

[0017] Pyridoxine and its salts, and chondroitin sulfate and its salts may be used singly or in combination of two or more.

[0018] When the eyewash composition of the present disclosure contains component (C), its content is not limited as long as the effects of the present disclosure are obtained, but the content of component (C) in the eyewash composition is preferably 0.005 to 0.1 w / v%, more preferably 0.01 to 0.08 w / v%, and even more preferably 0.02 to 0.08 w / v%. The content of component (C) is also not limited as long as the effects of the present disclosure are obtained, but the content is preferably 0.1 to 7 parts by mass, more preferably 0.3 to 5 parts by mass, and even more preferably 0.5 to 3 parts by mass per part by mass of component (A) in the eyewash composition.

[0019] Furthermore, although not limiting the present disclosure, more preferably, at least one member selected from the group consisting of pyridoxine and its salts is present in the eyewash composition at a concentration of 0.001 to 0.02 w / v%, even more preferably 0.005 to 0.02 w / v%, and particularly preferably 0.005 to 0.01 w / v%.

[0020] Furthermore, although not limiting the present disclosure, more preferably, at least one selected from the group consisting of chondroitin sulfate and its salts is present in the eyewash composition at 0.005 to 0.05 w / v%, even more preferably 0.02 to 0.05 w / v%, and particularly preferably 0.03 to 0.05 w / v%.

[0021] The eyewash composition of the present disclosure may further contain any other component acceptable for use in eye drops or eyewashes. Examples of such other components include, but are not limited to, buffers, stabilizers, isotonicity agents, solvents (e.g., water), pH adjusters, medicinal ingredients, preservatives, irritants, thickeners, etc. The other components may be selected appropriately depending on the purpose, etc., as long as they do not interfere with the effects of the present disclosure. They may be used alone or in combination with two or more other components, and the amounts of these may be determined appropriately. Note that the components (A) to (C) are also known as medicinal ingredients, etc., depending on the component, but in the present disclosure, the components (A) to (C) are not included in the optional other components.

[0022] Examples of such other components include buffers, such as boric acid and borax. A single buffer may be used, or two or more buffers may be used in combination. For example, when the composition contains boric acid, the content of boric acid is not limited as long as it does not impair the effects of the present disclosure, and is preferably 0.1 to 2.5 w / v%, and more preferably 0.5 to 2 w / v% in the composition. For example, when the composition contains borax, the content of borax is not limited as long as it does not impair the effects of the present disclosure, and is preferably 0.005 to 0.5 w / v%, and more preferably 0.005 to 0.05 w / v% in the composition. The composition may or may not contain a buffer other than boric acid or borax. Alternatively, only one of boric acid and borax may be blended.

[0023] Examples of the other components include stabilizers such as polysorbate (polysorbate 80, polysorbate 60, etc.), polyoxyethylene (POE) hydrogenated castor oil (PO Examples of stabilizers include POE (80) hydrogenated castor oil, POE (60) hydrogenated castor oil, etc. (the number in parentheses indicates the average number of moles of ethylene oxide added), POE polyoxypropylene glycol, and sodium edetate (including hydrate). These may be used alone or in combination of two or more. When the composition contains a stabilizer, the content is not limited as long as it does not impair the effects of the present disclosure, and is preferably 0.01 to 0.5 w / v%, and more preferably 0.02 to 0.5 w / v% of the composition. When the composition contains a stabilizer, it may contain only one or only two selected from polysorbate, POE hydrogenated castor oil, sodium edetate, and POE polyoxypropylene glycol. Furthermore, when polysorbate is contained, the composition may be prepared without blending POE hydrogenated castor oil, sodium edetate, and / or POE polyoxypropylene glycol.

[0024] Examples of such other ingredients include medicinal ingredients such as amino acids, anti-inflammatory agents, vitamins, antihistamines, etc. These may be used alone or in combination of two or more.

[0025] Although not limiting the present disclosure, examples of amino acids include amino acids and their salts, such as glutamic acid and its salts; and amino acid analogs, such as taurine. These may be used alone or in combination of two or more. The eyewash composition of the present disclosure can also be prepared without adding an amino acid and / or its salt. The term "amino acid" as used herein refers to an amino acid that can be a structural unit of a protein and has both an amino group and a carboxyl group, and includes, for example, L-aspartic acid. The eyewash composition of the present disclosure can also be prepared without adding an amino acid analog.

[0026] Although not limiting the present disclosure, examples of anti-inflammatory agents include zinc sulfate, zinc lactate, epsilon-aminocaproic acid, allantoin, glycyrrhizic acid, and salts thereof. These may be used alone or in combination of two or more. Although not limiting the present disclosure, the composition preferably does not contain zinc sulfate and / or zinc lactate. The composition can also be prepared without incorporating epsilon-aminocaproic acid, allantoin, glycyrrhizic acid, and salts thereof.

[0027] Although not limiting the present disclosure, examples of vitamins include vitamin A (retinol palmitate, retinol acetate, retinol, retinal, retinoic acid, etc.), vitamin B (flavin adenine dinucleotide, cyanocobalamin, etc.), vitamin E (tocopherol acetate, tocopherol succinate, tocopherol nicotinate, tocopherol linoleate, etc.). These may be used alone or in combination of two or more. Although not limiting the present disclosure, the composition may also be prepared without blending at least one of the vitamins.

[0028] Although not limiting the present disclosure, examples of antihistamines include chlorpheniramine and its salts (e.g., chlorpheniramine maleate), diphenhydramine and its salts (e.g., diphenhydramine hydrochloride), etc. These may be used alone or in combination of two or more. The composition of the present disclosure can also be prepared without incorporating an antihistamine.

[0029] When the composition of the present disclosure contains a medicinal ingredient, the content of the medicinal ingredient is not limited as long as it does not interfere with the effects of the present disclosure. The content of the medicinal ingredient in the composition is preferably 0.02 to 0.25 w / v%, more preferably 0.1 to 0.25 w / v%, and even more preferably 0.2 to 0.25 w / v%, for example.

[0030] Examples of such other components include preservatives, such as quaternary ammonium salt preservatives (benzalkonium chloride, benzethonium chloride, etc.), parahydroxybenzoic acid esters (parahydroxybenzoic acid esters such as methyl parahydroxybenzoate, salts of parahydroxybenzoic acid esters (alkali metal salts such as sodium salts), etc.), chlorobutanol, and sorbic acids (sorbic acid, salts of sorbic acid (alkali metal salts such as potassium salts), etc.). These may be used alone or in combination of two or more. Although not limiting the present disclosure, the eyewash composition of the present disclosure can also be prepared without incorporating a preservative.

[0031] An example of such an irritant is an aldehyde such as propionaldehyde. The eyewash composition of the present disclosure may contain an irritant, or may be prepared without the incorporation of an irritant.

[0032] Examples of such other components include thickeners, such as alginic acid and its salts, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, carboxyvinyl polymers, salts thereof, and glycerin. These may be used alone or in combination of two or more. The eyewash composition of the present disclosure can also be prepared without blending these thickeners.

[0033] The eyewash composition of the present disclosure can be produced by mixing the components (A) and (B), and optionally the component (C), and the other components. The mixing method is not limited as long as these components can be mixed, and they may be mixed according to a conventional procedure.

[0034] The pH of the eyewash composition of the present disclosure is not limited as long as it is within a range that can be used as an eye drop or eyewash, but examples of such a pH at room temperature (25°C) include pH 5 to 8, preferably pH 5.5 to 7, more preferably pH 5.5 to 6.5, even more preferably pH 5.5 to 6, and particularly preferably pH 5.5 to 5.8.

[0035] The eyewash composition of the present disclosure is in liquid form at room temperature, and its method of use is not limited as long as it can cleanse the eyes in a manner similar to that known in the art. It is typically used for eyewashing using an eyewash cup (eyecup) or by eye drops.

[0036] The eyewash composition of the present disclosure may be used with or without contact lenses, regardless of whether they are hard or soft contact lenses.

[0037] The eyewash composition of the present disclosure is not limited as long as it can be used as described above, but when used with an eyewash cup, it may be placed in a conventional, commonly used eyewash container (e.g., including a container body and a cap). The volume of the container is also not limited, but from the viewpoint of ease of use, the volume is preferably 450 to 550 mL, for example.

[0038] Washing the eyes using an eyewash cup can be done according to a normal procedure, for example, by pouring an appropriate amount of the eyewash composition of the present disclosure from the container into the eyewash cup, for example, 4 to 6 mL per eye, and then pressing the cup against the area around one eye to bring the eyewash composition in the cup into contact with the eye, followed by blinking several times. The number of times the composition is used per day is not limited, and can be, for example, 1 to 6 times per eye per day.

[0039] When the eyewash composition of the present disclosure is used for eyewashing by instillation, the composition is usually contained in an eyedropper container for use, from the viewpoint of ease of use. The container is not limited as long as it can contain a substance and be capable of instilling it into the eye, and examples thereof include eye drop containers (e.g., a type in which at least two of the container body, inner stopper (nozzle), and cap are integrated) that are used for conventionally known eye drops, eye drop-type eyewashes, etc. The volume of the container is also not limited, but from the viewpoint of ease of use, a volume of 8 to 20 mL is exemplified.

[0040] Eyewashing by instillation can be performed according to standard methods, by instilling 4 to 6 drops of the eyewash composition of the present disclosure per eye at a time. The amount of each drop is not limited, but a preferred amount is 35 to 40 μL per drop. The number of times the composition is used per day is also not particularly limited, and examples include 2 to 8 times per day per eye.

[0041] According to the eyewash composition of the present disclosure, the cooling sensation can be prolonged by using the components (A) and (B) in combination. Furthermore, according to the eyewash composition of the present disclosure, the cooling sensation can be prolonged by using the components (A) and (B) in combination. Furthermore, according to the eyewash composition of the present disclosure, the cooling sensation can be prolonged by using the component (C) together with the components (A) and (B). If the composition further contains the aforementioned medicinal ingredients, the beneficial effects of the medicinal ingredients can also be obtained. [Example]

[0042] The present disclosure will be described in more detail below with reference to examples, but the present disclosure is not limited thereto.

[0043] Test Example 1: Cooling sensation Preparation of eyewash composition The components were mixed according to the blending ratios shown in Table 1 below, and the resulting mixture was passed through a sterilizing filter to obtain eyewash compositions (Examples 1 to 3, Comparative Examples 1 and 2). The pH of each composition was measured immediately after production. The pH was measured at room temperature (25°C) using a tabletop pH meter F-52 (manufactured by Horiba, Ltd.).

[0044] Evaluation of cooling sensation Six panelists washed their eyes with each eyewash composition for 30 seconds according to a typical eyewashing method using an eyecup (5 mL per eye, both eyes used without eye contact). The time the cooling sensation continued after washing was measured (the time the panelists felt the cooling sensation). The cooling sensation duration when the eyewash composition of Comparative Example 1 was used was defined as 100, and the value (cooling sensation extension rate) when each eyewash composition was used was calculated according to the following formula (rounded to one decimal place): Prolongation rate of cool sensation (%) = duration of cool sensation when using each eyewash composition × 100 / duration of cool sensation when using the eyewash composition of Comparative Example 1

[0045] result The results are shown in Table 1.

[0046] [Table 1]

[0047] As shown in Table 1, the eyewash composition of Comparative Example 2, which used a cooling agent in combination with hydroxyethyl cellulose, had a cooling sensation extension rate of 75, which was inferior to the duration (cool sensation extension of 100) of the eyewash composition of Comparative Example 1, which used a cooling agent but did not use hydroxyethyl cellulose.

[0048] In contrast, the eyewash composition of Example 1, which used a combination of a cooling agent and sodium hyaluronate, had a cooling sensation extension rate of 120, indicating that the cooling sensation could be maintained for a longer period of time than the eyewash composition of Comparative Example 1. Since both the hydroxyethyl cellulose used in Comparative Example 2 and the sodium hyaluronate used in Example 1 are known as thickeners (thickening agents), it was expected that similar results would be obtained when hydroxyethyl cellulose was used and when sodium hyaluronate was used. However, contrary to expectations, as mentioned above, the use of hydroxyethyl cellulose in combination did not result in a longer cooling sensation, but the use of sodium hyaluronate did. Furthermore, the eyewash compositions of Examples 2 and 3, which contained a higher amount of sodium hyaluronate than Example 1, demonstrated a further longer cooling sensation. Furthermore, even when using the eyewash composition of Example 2 to wash eyes while wearing soft contact lenses, the cooling sensation extension rate was confirmed to be similar to that of Example 2, in which the eyes were washed with the naked eye.

[0049] This indicates that the cooling sensation can be maintained for a longer period of time by using a cooling agent in combination with hyaluronic acid.

[0050] Test example 2: Focus adjustment function, dryness, foreign body sensation Preparation of eyewash composition The components were mixed according to the blending ratios shown in Table 2 below, and the resulting mixtures were passed through a sterilizing filter to obtain eyewash compositions (Examples 2 to 5, Comparative Examples 1, 3, and 4). The pH was measured in the same manner as in Test Example 1. Note that the chondroitin sulfate ester Na in the table was non-standard sodium chondroitin sulfate (weight average molecular weight 20,000).

[0051] Evaluation of focus adjustment function, dryness, and foreign body sensation Nine panelists who worked on a computer (known as PC work) for more than eight hours a day were asked to wash their eyes with each eyewash composition three times a day for one week, following the general method of washing eyes using an eyecup (5 mL per eye, used on both eyes without contact with the naked eye).

[0052] The time required for focusing (the number of seconds until focusing) before using the eyewash composition (before the start of the test: initial stage) and after one week of use was measured using an accommodometer (model number HS-9E, manufactured by Kowa Co., Ltd.). The accommodometer is a device used to test focusing function (ability). The improvement rate of focusing was calculated according to the following formula, and the effect of improving focusing was evaluated by applying the average improvement rate of the nine subjects to the following criteria. Focus adjustment improvement rate (%) = (initial focus adjustment time (seconds) - focus adjustment time after 1 week of use (seconds)) x 100 / initial focus adjustment time (seconds)

[0053] <Standards> ×: 0 to less than 5% △: 5% or more but less than 10% 〇: 10% or more but less than 20% ◎: 20% or more but less than 30% ◎◎: 30% or more

[0054] Regarding dry eye sensation and foreign body sensation, a questionnaire was conducted to assess whether the dry eye sensation and foreign body sensation had improved after one week of use compared to the initial state. The questionnaire was conducted on a five-point scale of "greatly improved," "improved," "slightly improved," "neither improved nor deteriorated," and "worsened." The number of panelists who answered "greatly improved" to "improved" was used as a score for the improvement of dry eye sensation and the improvement of foreign body sensation in the eyes, respectively. The scores were applied to the following criteria to evaluate the improvement effect. The degree of improvement was compared among panelists in advance to unify the criteria.

[0055] <Standards> ×: Score 1 or less △: Score 2~3 ○: Score 4~5 ◎: Score 6-7 ◎◎: Score 8~9

[0056] result The results are shown in Table 2.

[0057] [Table 2]

[0058] The eyewash composition of Comparative Example 1 listed in Table 2 is the same as Comparative Example 1 listed in Table 1 above. As shown in Table 2, the eyewash composition of Comparative Example 1 containing a cooling agent and the eyewash composition of Comparative Example 3, which further contained pyridoxine hydrochloride in Comparative Example 1, showed poor accommodation improvement results, with the results being x or △, and the desired improvement effects were not achieved. Furthermore, these eyewash compositions showed poor improvement results in dry eye sensation and foreign body sensation, with the results being x or △, and the desired improvement effects were not achieved. Furthermore, the eyewash composition of Comparative Example 4, which did not contain a cooling agent or pyridoxine hydrochloride but contained sodium hyaluronate, showed poor accommodation improvement results, with the results being ○, and the results being △, and the improvement results in dry eye sensation and foreign body sensation were better than those of the eyewash compositions of Comparative Examples 1 and 3, but the improvement effects were insufficient.

[0059] In contrast, the eyewashes of Examples 2 and 3, which contained a cooling agent and sodium hyaluronate, The results of the improvement in accommodation, dry eye sensation, and foreign body sensation were all rated as ⊚. From this, it was found that the combination of a cooling agent and sodium hyaluronate can improve accommodation function, dry eye sensation, and foreign body sensation. Furthermore, from this, it was found that the combination of a cooling agent and sodium hyaluronate is also useful for improving dry eye symptoms. In the eyewash composition of Example 4, which further contains pyridoxine in Example 2, the results of the improvement in accommodation, dry eye sensation, and foreign body sensation were all rated as ⊚. It was found that the improvement in accommodation, dry eye sensation, and foreign body sensation was more significant than that of the eyewash composition of Example 2. Furthermore, in the eyewash composition of Example 5, which further contains sodium chondroitin sulfate in Example 4, the results of the improvement in accommodation, dry eye sensation, and foreign body sensation were all rated as ⊚. It was found that the improvement in accommodation, dry eye sensation, and foreign body sensation was also significantly significant. Furthermore, even when washing the eyes with the eyewash compositions of Examples 2, 4, and 5 while wearing soft contact lenses, the focusing function, dryness of the eyes, and foreign body sensation were improved to the same extent as in Examples 2, 4, and 5, where the eyes were washed with the naked eye.

[0060] From this, it was found that the eye symptoms associated with VDT work can be improved by using a combination of a cooling agent and hyaluronic acid.Furthermore, it was found that the eye symptoms associated with VDT work can be improved by using pyridoxine or chondroitin in combination.Furthermore, as can be seen from Table 2, it was found that the eye symptoms associated with VDT work can be effectively improved despite the very small amounts of pyridoxine and chondroitin blended.Furthermore, although not shown in the results, the eyewash compositions of each Example shown in Table 2 were able to maintain a cooling sensation for a longer period of time than the eyewash composition of Comparative Example 1.

[0061] Test Example 3: Eye fatigue Preparation of eyewash composition The components were mixed according to the blending ratios shown in Table 3 below, and the resulting mixture was passed through a sterilizing filter to obtain eyewash compositions (Examples 4, 6, and 7, and Comparative Examples 1, 3, and 5). The pH was measured in the same manner as in Test Example 1.

[0062] Assessment of eye fatigue Six panelists were asked to work on a personal computer (PC work) for three hours, and then washed their eyes with each eyewash composition according to a common eyewashing method using an eyecup (5 mL per eye, used on both eyes without contact with the naked eye). 15 minutes after washing, a questionnaire was administered to assess whether fatigue had improved. The questionnaire was conducted on a five-point scale: "greatly improved," "improved," "slightly improved," "neither improved nor deteriorated," and "worsened." The number of panelists who answered "greatly improved" to "improved" was used as a score for fatigue improvement. The scores were applied to the following criteria to evaluate the effect of improving eye fatigue. The degree of improvement was compared among panelists in advance to standardize the criteria.

[0063] <Standards> ×: Score 1 or less △: Score 2~3 ○: Score 4~5 ◎: Score 6

[0064] result The results are shown in Table 3.

[0065] [Table 3]

[0066] The eyewash compositions of Comparative Examples 1 and 3 listed in Table 3 are the same as those of Comparative Examples 1 and 3 listed in Tables 1 and 2. As shown in Table 3, the eyewash composition of Comparative Example 1 and the eyewash composition of Comparative Example 3, which was the eyewash composition of Comparative Example 1 blended with pyridoxine hydrochloride, both showed poor results in improving fatigue. In addition, the eyewash composition of Comparative Example 5, which was blended with sodium hyaluronate without blending a cooling agent, also showed poor results in improving fatigue.

[0067] In contrast, the eyewash composition of Example 6, which further contains pyridoxine hydrochloride and sodium hyaluronate in the eyewash composition of Comparative Example 1, showed a fatigue improvement result of ◯, effectively improving the fatigue. Furthermore, the eyewash compositions of Examples 4 and 7, which contain a larger amount of sodium hyaluronate than Example 6, showed a fatigue improvement result of ⊚, further significantly improving the fatigue. Furthermore, even when washing the eyes with the eyewash compositions of Examples 4 and 7 while wearing soft contact lenses, the fatigue was significantly improved to the same extent as in Examples 4 and 7, where the eyes were washed with the naked eyes.

[0068] This also explains why combining a cooling agent with sodium hyaluronate and pyridoxine hydrochloride is effective. It was found that by using them in combination, eye symptoms associated with VDT work could be improved. Furthermore, although not shown in the results, the eyewash compositions of Examples 4, 6 and 7 were also able to maintain a refreshing feeling for a longer period of time than the eyewash composition of Comparative Example 1.

[0069] Prescription example The eyewash compositions shown in Table 4 were prepared, and the cooling sensation extension rate, eye fatigue, focusing ability, dryness, and foreign body sensation were evaluated in the same manner as in Test Examples 1 to 3. It was found that the eyewash compositions of all of Formulation Examples 1 to 8 were able to extend the duration of the cooling sensation and significantly improve fatigue, focusing ability, dryness, and foreign body sensation.

[0070] [Table 4]

Claims

[Claim 1] (A) at least one selected from the group consisting of hyaluronic acid and salts thereof; (B) a cooling agent, and Contains at least one selected from the group consisting of pyridoxine and salts thereof, The content of the component (A) is 0.02 to 0.03 w / v %, The content of the component (B) per 1 part by mass of the component (A) is 0.25 to 0.35 parts by mass. An eyewash composition for improving eye symptoms associated with VDT (Visual Display Terminals) work.

Images